argenx SE (ARGNF)
USD 697.42
(0.33%)
USD 697.42
(0.33%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 444.95 Million USD | 38.8% |
| 2022 | 320.56 Million USD | 1.43% |
| 2021 | 316.05 Million USD | -47.91% |
| 2020 | 606.75 Million EUR | 41.58% |
| 2019 | 428.56 Million EUR | 835.17% |
| 2018 | 45.82 Million EUR | 47.05% |
| 2017 | 31.16 Million EUR | -30.11% |
| 2016 | 44.59 Million EUR | 369.65% |
| 2015 | 9.49 Million EUR | -7.36% |
| 2014 | 10.24 Million EUR | 124.36% |
| 2013 | 4.56 Million EUR | -27.24% |
| 2012 | 6.27 Million EUR | 55.3% |
| 2011 | 4.04 Million EUR | 99.25% |
| 2010 | 2.02 Million EUR | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 534.31 Million USD | 0.0% |
| 2024 Q1 | - USD | -100.0% |
| 2023 FY | 444.95 Million USD | 38.8% |
| 2023 Q1 | - USD | -100.0% |
| 2023 Q2 | 335.74 Million USD | 0.0% |
| 2023 Q3 | - USD | -100.0% |
| 2023 Q4 | 444.95 Million USD | 0.0% |
| 2022 Q4 | 320.56 Million USD | 0.0% |
| 2022 Q2 | 279.01 Million USD | 0.0% |
| 2022 FY | 320.56 Million USD | 1.43% |
| 2022 Q3 | - USD | -100.0% |
| 2021 Q2 | 261.08 Million USD | 0.0% |
| 2021 FY | 316.05 Million USD | -47.91% |
| 2021 Q4 | 316.05 Million USD | 0.0% |
| 2020 Q2 | 456.61 Million EUR | 0.0% |
| 2020 FY | 606.75 Million EUR | 41.58% |
| 2020 Q4 | 606.75 Million EUR | 0.0% |
| 2019 FY | 428.56 Million EUR | 835.17% |
| 2019 Q4 | 382.59 Million EUR | 0.0% |
| 2019 Q2 | 390.84 Million EUR | 0.0% |
| 2018 FY | 45.82 Million EUR | 47.05% |
| 2018 Q4 | 45.82 Million EUR | 0.0% |
| 2018 Q2 | 31.28 Million EUR | 0.0% |
| 2017 Q2 | 40.3 Million EUR | 0.0% |
| 2017 FY | 31.16 Million EUR | -30.11% |
| 2017 Q4 | 31.16 Million EUR | 0.0% |
| 2016 Q4 | 44.59 Million EUR | 0.0% |
| 2016 Q2 | 46.64 Million EUR | 0.0% |
| 2016 FY | 44.59 Million EUR | 369.65% |
| 2015 Q4 | 9.49 Million EUR | 0.0% |
| 2015 FY | 9.49 Million EUR | -7.36% |
| 2015 Q2 | 11.59 Million EUR | 0.0% |
| 2014 Q1 | 3.66 Million EUR | -19.7% |
| 2014 Q4 | 10.24 Million EUR | 0.0% |
| 2014 Q2 | 14.12 Million EUR | 285.0% |
| 2014 FY | 10.24 Million EUR | 124.36% |
| 2013 Q4 | 4.56 Million EUR | 0.0% |
| 2013 FY | 4.56 Million EUR | -27.24% |
| 2012 FY | 6.27 Million EUR | 55.3% |
| 2011 FY | 4.04 Million EUR | 99.25% |
| 2010 FY | 2.02 Million EUR | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -1621855.309% |
| Arch Therapeutics, Inc. | 9.46 Million USD | -4600.557% |
| Evofem Biosciences, Inc. | 72.47 Million USD | -513.971% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | -54914.132% |
| Rebus Holdings, Inc. | 5.24 Million USD | -8388.192% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | -653.975% |
| Qrons Inc. | 1.48 Million USD | -29788.299% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 1.22 Million USD | -36186.599% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | -493.901% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -995405.191% |
| Skye Bioscience, Inc. | 14.07 Million USD | -3061.908% |
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | -734.727% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | -4543.602% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | -105446.673% |
| SQZ Biotechnologies Company | 50.03 Million USD | -789.208% |
| Intellipharmaceutics International Inc. | 12 Million USD | -3605.218% |
| Propanc Biopharma, Inc. | 3.85 Million USD | -11452.896% |
| Mesoblast Limited | 188.44 Million USD | -136.118% |
| Marizyme, Inc. | 26.67 Million USD | -1568.001% |
| Genus plc | 485 Million USD | 8.258% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | -7515.606% |
| Pharming Group N.V. | 244.07 Million USD | -82.302% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | -22035.434% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | -17582.552% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | -11609.237% |
| ContraFect Corporation | 32.53 Million USD | -1267.775% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | -22357.437% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | -11524.658% |
| IMV Inc. | 37.93 Million USD | -1072.998% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | -3677.752% |
| MultiCell Technologies, Inc. | 1617.67 USD | -27505571.738% |
| ONE Bio Corp. | 27.49 Million USD | -1518.25% |
| Accustem Sciences Inc. | 1.07 Million USD | -41128.217% |
| RVL Pharmaceuticals plc | 77.41 Million USD | -474.746% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 2.11 Million USD | -20937.186% |
| Q BioMed Inc. | 8.13 Million USD | -5370.974% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | -436.506% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | -8546.482% |
| Biomind Labs Inc. | 1.49 Million USD | -29590.874% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | -274.783% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | -4820.83% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | -2317.763% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | -30931.669% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -313036.282% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -221140.975% |
| Curative Biotechnology, Inc. | 5.74 Million USD | -7643.906% |
| GB Sciences, Inc. | 5.41 Million USD | -8113.13% |
| Alpha Cognition Inc. | 7.16 Million USD | -6110.259% |
| HST Global, Inc. | 593.59 Thousand USD | -74858.937% |
| CSL Limited | 18.62 Billion USD | 97.61% |
| Wesana Health Holdings Inc. | 1.25 Million USD | -35236.203% |
| Halberd Corporation | 728.71 Thousand USD | -60959.338% |
| Enzolytics Inc. | 365.26 Million USD | -21.815% |
| Agentix Corp. | 2.51 Million USD | -17623.213% |
| Resverlogix Corp. | 67.39 Million USD | -560.204% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | -52950.438% |
| MetaStat, Inc. | - USD | -Infinity% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | -25859.802% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | -1698.07% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | -3638.11% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | -12040.002% |
| AVAX Technologies, Inc. | 3.99 Million USD | -11041.197% |
| Zenith Capital Corp. | 27.56 Thousand USD | -1613854.079% |
| Genscript Biotech Corporation | 1.32 Billion USD | 66.441% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -186341.878% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | -11815.226% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | -65253.816% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | -16308.92% |
| Kadimastem Ltd | 3.5 Million USD | -12595.232% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -664710.471% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 50.26 Million USD | -785.228% |
| BioStem Technologies, Inc. | 15.9 Million USD | -2697.613% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 464.69 Thousand USD | -95650.367% |
| LadRx Corporation | 2.2 Million USD | -20120.193% |
| Cell Source, Inc. | 15.8 Million USD | -2714.949% |
| Regen BioPharma, Inc. | 5.45 Million USD | -8052.845% |
| Regen BioPharma, Inc. | 5.45 Million USD | -8052.845% |
| NovAccess Global Inc. | 7.86 Million USD | -5560.427% |
| Affymax, Inc. | 8.87 Million USD | -4915.793% |
| Itoco Inc. | 1.65 Million USD | -26815.327% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | -21588.37% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | -7255.778% |
| Mobile Lads Corp. | 1.31 Million USD | -33775.296% |
| CytoDyn Inc. | 127.89 Million USD | -247.906% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -1064401.543% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | -28306.38% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | -3928.423% |
| SYBLEU INC | 681.41 Thousand USD | -65198.285% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | -7192.001% |
| International Stem Cell Corporation | 5.27 Million USD | -8331.893% |
| Bioxytran, Inc. | 3.24 Million USD | -13592.907% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | -71000.128% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | -9536.971% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | -985.352% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | -1898.433% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | -21868.69% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | -8022.508% |
| Neutra Corp. | 973.52 Thousand USD | -45604.956% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | -1433.521% |
| PureTech Health plc | 125.58 Million USD | -254.308% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | -11742.859% |
| IXICO plc | 1.9 Million USD | -23314.875% |
| IntelGenx Technologies Corp. | 20.52 Million USD | -2067.427% |
| Gelesis Holdings, Inc. | 103.32 Million USD | -330.637% |
| CSL Limited | 18.62 Billion USD | 97.61% |
| Cellectis S.A. | 249.36 Million USD | -78.43% |